# Mechanism of Action of Ocrelizumab in Multiple Sclerosis

> **NCT03344094** · — · COMPLETED · sponsor: **University of Chicago** · enrollment: 30 (actual)

## Conditions studied

- Multiple Sclerosis
- Immune System Diseases

## Interventions

- **DRUG:** ocrelizumab

## Key facts

- **NCT ID:** NCT03344094
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-23
- **Primary completion:** 2019-04-10
- **Final completion:** 2019-04-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344094, "Mechanism of Action of Ocrelizumab in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03344094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*